Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
National Institute of Allergy and Infectious Diseases (NIAID)
With
North American Biologicals Inc
Passive antibody therapy has been used with limited success in treating advanced HIV disease in adults. HIVIG is manufactured from HIV antibody-rich plasma taken from asymptomatic donors. It is hypothesized that HIVIG will decrease the viral burden of moderately advanced HIV-positive children.
Children are randomized to receive HIVIG every 4 weeks for 6 months at one of three dose levels, then are followed for 3 months after the final infusion.
Age
2–12
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Concurrent Medication:
Required:
PCP prophylaxis according to CDC guidelines.
Allowed:
Varicella-zoster immunoglobulin.
Hepatitis B immunoglobulin.
Prophylactic therapies not involving immunoglobulin.
